Screener / SEC EDGAR /CIK 0001232524 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Jazz Pharmaceuticals plc JAZZ

Compare with peers Embed
Planned sales, announced before they happen

4 trading plans running, 54 Form 144 notices for $104.4M

10-Q, 10-K and Form 144
Plans running now 4 Renee D. Gala, Robert Iannone, Neena M. Patil, Bruce C. Cozadd
Plans adopted 9 reported since May 1, 2023 Form 144 notices 54 $104.4M the sellers expected to sell

What JAZZ's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Jun 2, 2023 to Aug 5, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Mark D. Smith
Director
Ended 10b5-1 plan Jun 15, 2026 10-Q Aug 3, 2026
Renee D. Gala
President and Chief Executive Officer
Adopted 10b5-1 plan Jun 4, 2026 10-Q Aug 3, 2026
Robert Iannone
Executive Vice President, Global Head of Research and Development, Chief Medical Officer
Adopted 10b5-1 plan May 28, 2026 10-Q Aug 3, 2026
Mark D. Smith
Director
Adopted 10b5-1 plan Mar 9, 2026 10-Q May 5, 2026
Neena M. Patil
Executive Vice President and Chief Legal Officer
Adopted 10b5-1 plan Feb 26, 2026 10-Q May 5, 2026
Bruce C. Cozadd
Chairman
Adopted 10b5-1 plan Nov 26, 2025 10-K Feb 24, 2026
What the company wrote
The following is a summary of the material terms of the contracts, instructions or written plans for the purchase or sale of the company’s securities adopted or terminated by our officers (as defined in Rule 16a-1(f) under the Exchange Act) and directors during the quarter ended December 31, 2025: Type of Trading Arrangement Name and Position Date Action Rule 10b5-1* Expiration Date Total Ordinary Shares to be Sold Bruce C. Cozadd (Chairman) 11/26/2025 Adoption X 2/26/2027 Up to 72,000 * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Robert Iannone
Executive Vice President, Global Head of Research and Development, Chief Medical Officer
Ended 10b5-1 plan Dec 6, 2024 10-K Feb 26, 2025
Bruce Cozadd
Chairman and Chief Executive Officer
Adopted 10b5-1 plan Jun 5, 2024 10-Q Aug 1, 2024
Robert Iannone
Executive Vice President, Global Head of Research and Development
Adopted plan Mar 7, 2024 10-Q May 2, 2024
What the company wrote
The following is a summary of the material terms of the contracts, instructions or written plans for the purchase or sale of the Company’s securities adopted or terminated by our officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) and directors during the quarter ended March 31, 2024: Type of Trading Arrangement Name and Position Date Action Rule 10b5-1* Expiration Date Total Ordinary Shares to be Sold Robert Iannone March 7, 2024 Modification X March 7, 2025 10,681 Executive Vice President, Global Head of Research and Development * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
Robert Iannone
Executive Vice President Global Head of Research and Development
Ended 10b5-1 plan Aug 18, 2023 10-Q Nov 8, 2023
Bruce C. Cozadd
Chairman and Chief Executive Officer
Adopted 10b5-1 plan Aug 14, 2023 10-Q Nov 8, 2023
Neena M. Patil
Executive Vice President and Chief Legal Officer
Adopted 10b5-1 plan Jun 2, 2023 10-Q Aug 9, 2023
Show the other 4 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 19 filings checked since May 1, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 6, 2026 BRUCE COZADD
Director
68,808 $16.2M
Nov 4, 2026 PATRICIA CARR
Officer
1,413 $327K
Nov 3, 2026 RENEE D GALA
Officer, Director
1,000 $225K
Nov 2, 2026 Bruce C Cozadd
Officer
6,000 $1.3M
Oct 8, 2026 ANNE O'RIORDAN
Director
14,687 $3.4M
Oct 6, 2026 RENEE D GALA
Officer
2,000 $473K
Oct 1, 2026 Bruce C Cozadd
Officer
6,000 $1.4M
Sep 10, 2026 NEENA PATIL
Officer
1,200 $289K
Sep 8, 2026 Henderson Mary Elizabeth
Director
2,691 $664K
Sep 8, 2026 RENEE D GALA
Officer
2,000 $486K
Sep 1, 2026 Bruce C Cozadd
Officer
6,000 $1.5M
Aug 31, 2026 Kennedy Patrick
Director
3,507 $858K
Aug 31, 2026 Henderson Mary Elizabeth
Director
3,852 $942K
Aug 31, 2026 Smith Mark Douglas
Director
3,507 $858K
Aug 31, 2026 Cook Jennifer E.
Director
3,507 $858K
Aug 31, 2026 Hamill Laura
Director
3,507 $858K
Aug 31, 2026 McSharry Heather Ann
Director
3,507 $858K
Aug 31, 2026 Winningham Rick E
Director
3,507 $858K
Aug 31, 2026 ENRIGHT PATRICK G
Director
3,507 $858K
Aug 31, 2026 COZADD BRUCE C
Director
2,506 $613K
Aug 31, 2026 LOVE TED W
Director
1,527 $373K
Aug 31, 2026 RIEDEL NORBERT G
Director
3,507 $858K
Aug 27, 2026 ROBERT IANNONE
Officer
76,921 $19.2M
Aug 7, 2026 ORiordan Anne
Director
3,507 $882K
Aug 3, 2026 Bruce C Cozadd
Officer
6,000 $1.5M
Jul 1, 2026 Bruce C Cozadd
Officer
6,000 $1.4M
Jun 15, 2026 MARK D SMITH
Director
1,157 $267K
Jun 10, 2026 NEENA PATIL
Officer
1,200 $278K
Jun 1, 2026 Bruce C Cozadd
Officer
6,000 $1.4M
May 28, 2026 NEENA PATIL
Officer
1,192 $282K
May 28, 2026 SAMANTHA PEARCE
Officer
6,907 $1.6M
May 22, 2026 HEATHER MCSHARRY
Director
2,000 $482K
May 22, 2026 RICK WINNINGHAM
Director
2,741 $662K
May 1, 2026 Bruce C Cozadd
Officer
6,000 $1.2M
Apr 1, 2026 Bruce C Cozadd
Officer
6,000 $1.1M
Mar 9, 2026 PATRICIA CARR
Officer
1,287 $235K
Mar 5, 2026 Henderson Mary Elizabeth
Officer
2,643 $499K
Mar 5, 2026 Carr Patricia
Officer
2,723 $514K
Mar 3, 2026 Bruce C Cozadd
Officer
6,000 $1.1M
Feb 27, 2026 PATRICIA CARR
Officer
1,117 $213K
Feb 27, 2026 NORBERT RIEDEL
Director
3,415 $656K
Feb 26, 2026 Henderson Mary Elizabeth
Officer
10,116 $2.0M
Feb 26, 2026 NEENA PATIL
Officer
55,600 $10.7M
Feb 26, 2026 Carr Patricia
Officer
2,370 $466K
Dec 9, 2025 MARY ELIZABETH HENDERSON
Officer
2,238 $379K
Dec 5, 2025 PATRICIA CARR
Officer
4,660 $798K
Dec 1, 2025 O'Keefe Kenneth W
Director
1,249 $221K
Nov 26, 2025 BRUCE COZADD
Director
77,500 $13.8M
Nov 20, 2025 HEATHER MCSHARRY
Director
3,415 $607K
Nov 19, 2025 Henderson Mary Elizabeth
Officer
2,961 $377K
Nov 18, 2025 RICK WINNINGHAM
Director
5,500 $995K
Nov 18, 2025 PATRICIA CARR
Officer
5,319 $968K
Nov 18, 2025 Bruce C Cozadd
Officer
18,000 $3.3M
Nov 17, 2025 ROBERT IANNONE
Officer
7,159 $1.2M
Show the other 46 notices

From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/JAZZ/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.